Efficacy of Alirocumab for Thin-cap fibroatheroma in patients with coronary artery disease estImated by optical coherence tomography trial.
- Conditions
- vulnerable plaque in patients with coronary artery disease
- Registration Number
- JPRN-UMIN000029533
- Lead Sponsor
- Kobe University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 24
Not provided
Exclusion criteria are follows; 1: Patients who have been treated previously with at least one dose of any anti-PCSK9 monoclonal antibody 2: Patients had uncontrolled hypertension (systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg) between the time of PCI and randomization visit 3: Patients with LDL-C <70 mg/dL 4: Known hypersensitivity to alirocumab or rosuvastatin 5: Known history of hemorrhagic stroke 6: Currently under treatment for cancer 7: Patients on lipoprotein apheresis 8: Patients with severe liver or renal dysfunction 9: All contraindications to rosuvastatin as displayed in the respective national product labeling for these treatments 10: All contraindications to alirocumab as displayed in the respective national product labeling for these treatments 11: Pregnant or breast-feeding women 12: Considered by the investigator as inappropriate for this study for any reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the difference of fibrous cap thickness from baseline
- Secondary Outcome Measures
Name Time Method